A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

• Claire Harrison,
• Florian H. Heidel,
• Alessandro M. Vannucchi,
• Jean-Jacques Kiladjian,
• Amjad Hayat,
• Francesco Passamonti,
• Eibhlin Conneally,
• Thomas Kindler,
• Bruno Martino,
• Daniel B. Lipka,
• Tommaso Stefanelli,
• Pantelia Roussou,
• Davide Germano,
• Jacqueline Ewan,
• Vincent Ribrag

Affiliations

Claire Harrison

1 Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom

Florian H. Heidel

2 Internal Medicine C, University Medicine Greifswald, Germany

Alessandro M. Vannucchi

3 CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, University of Florence, Azienda Ospedaliera–Universitaria Careggi, Florence, Italy

Jean-Jacques Kiladjian

4 Hôpital Saint-Louis, Centre d’Investigations Cliniques, INSERM, Université de Paris, AP-HP, Paris, France

Amjad Hayat

5 Department of Haematology, University Hospital Galway, Galway, Republic of Ireland

Francesco Passamonti

6 Division of Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Eibhlin Conneally

7 Department of Haematology, St James Hospital, Dublin, Ireland

Thomas Kindler

8 Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Germany

Bruno Martino

9 Az.Osp. Bianchi-Melacrino’-Morelli, Reggio Calabria, Italy

Daniel B. Lipka

10 Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT) Heidelberg, Germany

Tommaso Stefanelli

11 Novartis Pharma AG, Basel, Switzerland

Pantelia Roussou

11 Novartis Pharma AG, Basel, Switzerland

Davide Germano

11 Novartis Pharma AG, Basel, Switzerland

Jacqueline Ewan

12 Novartis Pharmaceuticals UK Limited, London, United Kingdom

Vincent Ribrag

13 Institut Gustave Roussy, Villejuif, France